• Home
  • News
  • Get involved
  • About NICE
  • Find guidance
  • NICE Pathways
  • Quality standards
  • Into practice
  • QOF
  • Conditions and diseases

    • Blood and immune system
    • Cancer
    • Cardiovascular
    • Central nervous system
    • Digestive system
    • Ear and nose
    • Endocrine, nutritional and metabolic
    • Eye
    • Gynaecology, pregnancy and birth
    • Infectious diseases
    • Injuries, accidents and wounds
    • Mental health and behavioural conditions
    • Mouth and dental
    • Musculoskeletal
    • Respiratory
    • Skin
    • Urogenital
  • Public health

    • Accidents and injuries
    • Alcohol
    • Behaviour change
    • Cancer
    • Cardiovascular disease
    • Child health
    • Child social care
    • Chronic illness
    • Diabetes
    • Drugs
    • Environmental health
    • Infectious diseases
    • Maternal health
    • Mental health
    • Non-communicable diseases
    • Obesity and diet
    • Occupational health
    • Older people
    • Physical activity
    • Sexual health
    • Smoking and tobacco
    • Transport
    • Vaccine preventable diseases
    • Working with and involving communities
  • Treatments, Procedures and Devices

    • Bones and joint surgery
    • Cardiovascular surgery
    • Cardiovascular system drug treatments
    • Clinical devices
    • Diagnostic imaging
    • Diagnostic procedures
    • Digestive tract and other abdominal organs surgery
    • Drug treatments
    • Endocrine system and breast surgery
    • Eye surgery
    • Nervous system surgery
    • Radiotherapy
    • Screening
    • Surgical procedures
    • Therapeutic procedures
    • Tissue and organ donation
    • Urogenital surgery
  • Guidance by type

    • Clinical Guidelines
    • Technology appraisals
    • Public health guidance
    • Diagnostics guidance
    • Interventional procedures guidance
    • Medical technologies guidance
    • Cancer service guidance
    • Quality standards
  • Guidance by date

    • View the guidance by date published
About NICE guidance Close
NICE technology appraisal guidance
Issued: May 2012
TA256

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Select chapters to print, save or share
1 Guidance
2 The technology
3 The manufacturer's submission
4 Consideration of the evidence
5 Implementation
6 Related NICE guidance
7 Review of guidance
Appendix A: Appraisal Committee members, and NICE project team
Appendix B: Sources of evidence considered by the Committee
About this guidance
  • Download PDF PDF icon
  • Help
Accreditation logo
View the summary and implementation tools
Next
Previous

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta256

6 Related NICE guidance

Published

  • Dabigatran etexilate for the prevention of stroke or systemic embolism in atrial fibrillation. NICE technology appraisal guidance 249 (2012).

  • Thoracoscopic exclusion of the left atrial (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism. NICE interventional procedure guidance 400 (2011).

  • Dronedarone for the treatment of non-permanent atrial fibrillation. NICE technology appraisal guidance 197 (2010).

  • Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. NICE interventional procedure guidance 349 (2010).

  • The management of atrial fibrillation. NICE clinical guideline 36 (2006).

Next
Previous

Copyright © NICE 2013. All rights reserved.

Index